Moderna competitors

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX). David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

Dynamic, results-oriented leader with a strong track record of performance in turnaround and high-paced organizations. Utilize keen analysis and insights and team approach to drive organizational improvements and implementation of best practices. Superior interpersonal skills, capable of resolving multiple and complex (sales, human resources, legal, financial, operational) issues and motivating staff to peak performance. Excellent political connections developed as selected member of Fiorello LaGuardia's mayoral team.